Shanghai – October 20, 2025 – Cooley advised Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of antibody-drug conjugates (ADCs), on its global collaboration agreement with Samsung Bioepis to develop, manufacture and commercialize two ADC assets: TJ108, a bispecific and dual-payload ADC, and another asset to be named. In addition, Samsung Bioepis will receive an exclusive license from Phrontline for one topoisomerase-1 inhibitor (TOP1i) payload, applied to Samsung Bioepis’ ADC pipeline.

Under the terms of the agreement, Phrontline will receive an upfront payment and be eligible to receive additional milestone payments tied to development and regulatory achievements.

Cooley lawyers Geoffrey Spolyar, Yiming Liu and Zack Gong led the team advising Phrontline, with invaluable support from Shawn Yu, Aaron Pomeroy and Alan Tamarelli.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.